{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-014916","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.734234+00:00","generated_at":"2026-06-11T10:26:20.887170+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProMIS Q2 net loss $2.3M; cash drops to $1.2M; PMN310 IND cleared","bullets":["Net loss $2.3M vs $2.7M YoY; R&D expense fell to $1.0M from $3.2M.","Cash and equivalents $1.2M at June 30, 2023, down from $5.9M at Dec 31, 2022.","PMN310 received FDA IND clearance in May 2023; Phase 1a planned subject to capital.","Preclinical data at AAIC 2023 showed PMN310 selectively targets toxic amyloid beta oligomers with potential for improved safety.","Shares delisted from TSX in July 2023; now trades solely on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-014916","json":"https://secwatch.observer/filing/0001558370-23-014916.json","markdown":"https://secwatch.observer/filing/0001558370-23-014916.md","text":"https://secwatch.observer/filing/0001558370-23-014916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/0001558370-23-014916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/pmn-20230814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:26:20.887170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60e702450a82bbf347cdd4bab1a09f85c475affa","claim":"ProMIS Neurosciences Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $2.3 million for the quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, ProMIS Neurosciences Inc. (the \"Company\") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three and six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023014916/0001558370-23-014916-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $2.3 million for the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}